"""

What are analysts expecting?

West Pharmaceutical Services, a U.S.-based maker of pharmaceutical packaging and delivery systems, is viewed mostly positively on Wall Street. Among the 17 analysts covering West Pharmaceutical shares, the consensus rating is “strong buy,” consisting of 14 strong buys, one moderate buy and two hold recommendations.

That said, the recommendation picture has weakened slightly from a month ago. The number of strong-buy ratings fell to 14 from 15. BNP Paribas, which initiated coverage last month, assigned the stock an “outperform” rating and a $447 price target.

Has the stock outperformed the market and its sector?

With a market value of $24.63 billion, the company’s shares have climbed 43.1% over the past 52 weeks and 27.2% year to date. Although the stock reached a 52-week high of $386 on July 23, it is still trading 9.4% below that peak.

  • The S&P 500 Index rose 18.7% and 12.1% over the same periods, respectively.
  • The State Street Health Care Select Sector SPDR ETF (XLV), which tracks the healthcare sector, gained 26.6% over the past 52 weeks and 12.1% year to date.

The comparison shows that West Pharmaceutical has delivered a stronger performance than both the broader market and its own sector. The rally has been driven in part by demand for high-value injection solutions used in GLP-1 class drugs and biologics.

What do sales and earnings expectations signal?

Second-quarter results and growth drivers

The company’s second-quarter net sales rose 13.8% year on year to $872.30 million. Net sales of High-Value Product (HVP) components also increased 19.4% to $424.10 million.

Management said generic GLP-1 products, especially in Asia, could become a new growth engine, while it expects high-teens growth this year in GLP-1 and non-GLP-1 HVP components. For the current quarter, analysts forecast diluted earnings per share to rise 11.2% year on year to $2.18.

Expectations are even stronger further out. Wall Street expects earnings per share to increase 22.5% to $8.93 in fiscal 2026 and then rise another 10.8% to $9.89 in fiscal 2027. The fact that the company has topped market estimates in each of the last four quarters is also supporting this outlook.

The average analyst price target of $401.31 points to 14.7% upside from current levels. The highest target, $459, suggests the potential gain could reach 31.2%.

"""